Exploring Next-Generation High DAR Dual Payload ADCs Featuring Novel Payloads to Enhance Efficacy, Overcome Resistance & Improve Safety - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Exploring Next-Generation High DAR Dual Payload ADCs Featuring Novel Payloads to Enhance Efficacy, Overcome Resistance & Improve Safety

12:30 pm - Monday 12th October 2026

Leveraging a cutting-edge cell free platform and novel payload classes to discover high-DAR dual payload ADCs aimed at overcoming resistance to single payload ADCs
Demonstrating synergistic efficacy of Topo1-based combinations with diverse mechanisms, including DDR inhibitors, to enhance anti-tumor activity
Validating improved preclinical efficacy of dual payload ADCs across in vitro and in vivo/PDX models to support their potential in resistant tumor settings

Speakers:

Krishna Bajjuri

Krishna Bajjuri

Senior Director, Chemistry

Sutro Biopharma